Volume 5 Supplement 1
DYSCERNE: developing clinical management guidelines for selected dysmorphic syndromes
© Griffiths et al; licensee BioMed Central Ltd. 2010
Published: 19 October 2010
The DYSCERNE Network of Centres of Expertise for dysmorphology (http://www.dyscerne.org), is developing clinical management guidelines for Williams (WS), Angelman (AS), Noonan (NS) and Kabuki (KS) syndromes. An initial scoping exercise identified these conditions as rare, complex, multi-system disorders, for which it was felt that affected patients, families and health/social care professionals would benefit from access to up-to-date evidence based management guidelines.
Published evidence from which to develop management recommendations for these conditions is very limited, and devising a systematic and robust methodology has been challenging. Our approach is based on the Scottish Intercollegiate Guidelines Network (SIGN) method, which we modified placing more emphasis on expert opinion and consensus, whilst maintaining systematic rigour and transparency of processes.
The development process includes:
- Identification of key management issues by guideline group leaders.
- Targeted, systematic literature searches using PubMed.
- Review, identification and grading of results by panel of invited experts.
- Consensus meetings at which experts present, discuss and agree recommendations.
- Initial drafting of guideline document which is circulated amongst experts and stakeholders for comments.
- Amendments incorporated and guidelines finalised.
- Guidelines piloted and evaluated.
- International dissemination.
The process has involved 49 experts from 8 countries reviewing between them, over 1000 papers. The WS guidelines are currently being piloted in 20 centres, by paediatricians and geneticists. The first draft of AS guidelines has been circulated for feedback. Consensus meetings for NS and KS will be held very shortly. The finished guidelines will be available from the DYSCERNE website.
This article is published under license to BioMed Central Ltd.